Modified release formulation

Abstract

Drug products in the form of modified release formulations comprising the drug substance (-)-(3aR,4S,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester (AFQ056), as well as processes for making such drug products are provided. The drug products are useful in treating patients with Parkinson's disease and exhibiting L-dopa induced dyskinesia.

1 . A stable modified release formulation comprising (—)-(3aR,4S,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester in free base form as active pharmaceutical ingredient and a modified release agent, such that the active pharmaceutical ingredient is released from the formulation in a controlled fashion over a period of 6 hours, or over a period of 7 hours, so that at least 80% of the active pharmaceutical ingredient has been released at the end of this period. 
     
     
         2 . The modified release formulation according to  claim 1  having the following release characteristics in water: about 14% to about 20% after 60 minutes; about 51% to about 61% after 180 minutes; about 67% to about 77% after 240 minutes; about 90% to about 95% after 360 minutes; and about 95% to about 99% after 420 minutes. The before mentioned release characteristics are obtained by using standard dissolution rate equipment (paddle according to e.g. USP) at 100 rpm with 900 ml of Water+0.5% LDAO. 
     
     
         3 . The modified release formulation according to  claim 1 , wherein the modified release agent is hydroxy propyl methylcellulose. 
     
     
         4 . The modified release formulation according to  claim 3  wherein the drug substance has a particle size distribution of x10≦50 μm, x50≦100 μm and x90≦200 μm. 
     
     
         5 . The modified release formulation according to  claim 4  that exhibits a similar or decreased release rate in ethanol containing media as compared to a aqueous media with 0.5% LDAO. 
     
     
         6 . The modified release formulation according to  claim 1  further comprising a coating. 
     
     
         7 . The modified release formulation according to  claim 1  in form of a single unit dosage form comprising about 25 mg to about 250 mg (—) -(3aR,4S,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester in free base form, about 69 mg to about 135 mg hypromellose (type 2208 characterized by viscosities between about 80 to about 120 cP (20° C.)), about 20 mg to about 160 mg lactose monohydrate, about 3 mg to about 38 mg sodium starch glycolate, about 2 mg to about 4.5 mg Magnesium stearate and about 1 mg to about 2.2 mg colloidal silicon dioxide. 
     
     
         8 . The modified release formulation according to  claim 7  wherein (—)-(3aR,4S,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester in free base form is present in an amount of about 25 -250 mg. 
     
     
         9 . The modified release formulation according to  claim 1  in single unit dosage form comprising equal to or less than 100 mg AFQ056 compressed to round tablets with a diameter of about 8 mm. 
     
     
         10 . The modified release formulation according to  claims 1  in single unit dosage form comprising more than 100 mg AFQ056 compressed to round tablets with a diameter of about 11 mm. 
     
     
         11 . A process for the production of a modified release formulation of  claim 1 , comprising
 (i) mixing AFQ056 with filler, binder and disintegrant in a high shear granulator   (ii) adding purified water under mixing   (iii) kneading the mixture in a high shear granulator   (iv) passing the granulate through a screen using a screening mill   (v) drying the granulate in a fluid bed dryer   (vi) mixing the dry granulate with a modified release agent, filler and glidant followed by consecutive sieving using screening mill and mixing in a diffusion mixer   (vii) sieving a lubricant and adding to the mixture from the diffusion mixer   (viii) forming the composition   
     
     
         12 . The modified release formulation according to  claim 1  for use in the treatment of Parkinson's disease L-dopa induced dyskinesia, Fragile X syndrome (Martin-Bell syndrome), dyskinesia in Fragile X syndrome, obsessive compulsory disorders, autism, cystitis, and for the treatment, prevention or delay of progression of acute, traumatic and chronic degenerative processes of the nervous system, such as Parkinson's disease, senile dementia, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis and multiple sclerosis, psychiatric diseases such as schizophrenia and anxiety, depression, pain, itch and drug abuse such as alcohol and nicotine abuse and cocaine use disorders.